Bio-Images Drug Delivery

Name

Bio-Images Drug Delivery

Legal name

BDD Pharma Ltd.

Website

https://bddpharma.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical CRO/CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical CRO services
• Drug formulation development
• GMP clinical manufacturing
• Phase I clinical trials
• Timed-release drug delivery

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services (CRO): Full-service CRO offering including clinical trial design, regulatory submissions (MHRA, REC, ARSAC), project management, site management, pharmacovigilance, monitoring, data management, biostatistics, and medical writing. Services delivered through their MHRA-accredited Phase I clinical unit in Glasgow.
2. Technology Licensing: Licensing of proprietary OralogiK™ and CologiK™ drug delivery platforms to pharmaceutical and biotech partners. Partners include Cingulate Inc. (CTx-1301 ADHD treatment) and Contera Pharma (CP-012 Parkinson's treatment). Revenue generated through development milestones and potential royalties.
3. GMP Manufacturing Services: Phase-appropriate GMP manufacturing of Investigational Medicinal Products (IMP) and placebos for early-phase clinical trials. Offers 'just in time' manufacturing services enabling small batches throughout clinical trials without extensive stability programmes. Includes analytical testing and QC release.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

BDD Pharma operates as an integrated Contract Research Organisation and Contract Development and Manufacturing Organisation (CRO/CDMO) delivering early-phase drug development. Its Lean Clinical Development™ pathway combines formulation development, phase-appropriate GMP manufacturing of clinical trial supplies, and Phase I clinical trials under a single contract. The offering is differentiated by two proprietary timed-release tablet-in-tablet platforms (OralogiK™ and CologiK™) and integrated gamma scintigraphy imaging for in vivo formulation performance assessment.

Product overview

BDD Pharma (formerly Bio-Images Drug Delivery) operates as an integrated Contract Research Organisation and Contract Development and Manufacturing Organisation (CRO/CDMO) offering the Lean Clinical Development™ pathway. This unified approach combines three core service pillars: formulation development leveraging proprietary timed-release technologies (OralogiK™ for programmable drug delivery and CologiK™ for colon targeting), GMP manufacturing of clinical trial supplies, and Phase I clinical trials with integrated CRO services. The company's differentiated capabilities include gamma scintigraphy imaging for real-time in vivo formulation assessment, adaptive trial designs (BDD Swift), and respiratory propellant studies. The portfolio spans early formulation prototyping through to clinical proof-of-concept, with recent milestones including the CTx-1301 ADHD treatment NDA filing and CP-012 Parkinson's program Phase 1b success.

Differentiator

Problem solved

Functional benefit

Products and services

• Lean Clinical Development™ Integrated development pathway combining formulation development, GMP manufacturing, and Phase I clinical testing under one cohesive strategy, eliminating handoffs between CROs and CDMOs to compress timelines for pharmaceutical and biotech clients.
• OralogiK™ Technology Platform Patented erosion-based timed-release tablet-in-tablet platform enabling programmable lag times of 1-12 hours and single or multiple pulse release profiles independent of GI pH, hydrodynamics, and microbiome; licensed to pharmaceutical partners for development of modified-release products.
• CologiK™ Technology Platform Patent-protected colon-targeted tablet-in-tablet technology using an enteric-coated erodible barrier layer, enabling consistent pH-independent delivery to the colon using inert, low-cost excipients and simple compression manufacture.
• GMP Manufacturing Services Phase-appropriate GMP manufacturing of Investigational Medicinal Products (IMP) and matching placebos for early-phase clinical trials, offering 'just-in-time' manufacturing of tablets, capsules, powder blends, and radiolabelled products with in-house Qualified Person batch release and analytical testing.
• Phase I Clinical Trials Early-phase clinical research services including First-in-Human, SAD/MAD, bioequivalence, food-effect, and adaptive trials conducted at an MHRA-accredited clinical unit in Glasgow, with industry-leading 80.2% screening-to-enrolment and 95%+ participant retention rates.
• CRO Services Full contract research organization services including clinical trial design, MHRA/REC/ARSAC regulatory submissions, project management, pharmacovigilance, monitoring, data management, biostatistics, and medical writing for early-phase clinical programs.
• Gamma Scintigraphy Imaging Clinical imaging technique using radiolabelled formulations to track drug delivery in vivo in real time, assessing formulation performance, gastric emptying, GI transit, and site/rate of drug release data that cannot be obtained from in vitro testing.
• BDD Swift Adaptive Clinical Trials Adaptive clinical trial design integrating formulation development, GMP manufacturing, and clinical testing, using real-time clinical data to inform formulation choices in successive arms within a single study for rapid iterative testing.
• Formulation Development Science-led formulation development services spanning conventional oral dosage forms, hot melt extrusion, modified-release formulations, and targeted GI delivery, supported by in-house analytical testing and 25 years of drug delivery expertise.
• Mucociliary Clearance Propellant Studies Clinical evaluation services for novel pMDI propellants using gamma scintigraphy to assess effects on mucociliary clearance, supporting development of environmentally friendly inhaled therapies.

Quantifiable outcome

• Average regulatory approval to first onsite screening under 4 weeks
• +4 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• University of EdinburghcoreStrategic or Co-development Partner · 7 April 2026Academic partnership led by Professor Jonathan Fallowfield (Chair of Translational Liver Research) for ISLANDS national MASLD registry and biobank. Professor Fallowfield serves as academic lead for the project aimed at recruiting 1,500 participants over five years.
• SQinnovationcoreStrategic or Co-development Partner · 17 February 2026Partnership for SQIN-furosemide, investigational subcutaneous furosemide formulation. BDD conducted head-to-head PK/PD study comparing SQIN-furosemide against IV Lasix at their Glasgow Phase I clinic.
• Cingulate Inc.flagshipStrategic or Co-development Partner · 6 August 2025Licensing partnership for OralogiK™ technology in CTx-1301, a triple-pulse dexmethylphenidate treatment for ADHD. BDD conducted formulation work and Phase 1 scintigraphic studies. NDA filed with FDA in 2025 with PDUFA date May 2026. First product based on BDD technology approaching market.
• Monument TherapeuticsminorStrategic or Co-development Partner · 26 November 2024Partnership for MT1988, novel treatment for cognitive impairment associated with schizophrenia. BDD conducted Phase 1 trial with positive results reported June 2025.
• Contera PharmaflagshipStrategic or Co-development Partner · 27 September 2023Licensing partner for OralogiK™ technology in CP-012, delayed pulsatile levodopa/carbidopa tablet for Parkinson's disease. BDD conducted Phase 1b pharmacoscintigraphic study demonstrating successful delayed overnight delivery. Contera holds license to BDD's OralogiK™ technology for CP-012 programme.
• NHS Greater Glasgow and ClydecoreStrategic or Co-development PartnerNHS partnership for ISLANDS project providing clinical leadership through consultants in hepatology and gastroenterology. Participant identification centres across Scotland's NHS health boards.

Scale indicators6 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Glatt Group: Glatt operates CDMO and formulation development services with strengths in solid dosage forms, modified release, and process technology—comparable to BDD's oral drug product formulation development and GMP manufacturing offerings.
• Quotient Sciences: Quotient Sciences operates an integrated formulation-to-clinical-translational molecule development platform combining drug product formulation, GMP manufacturing, and early clinical testing within one operating footprint, directly comparable to BDD's Lean Clinical Development model.
• Upperton Pharma Solutions: UK-based Upperton Pharma Solutions provides formulation development and GMP clinical trial material manufacturing for oral and nasal dosage forms, closely overlapping BDD's drug product CDMO offering for early-phase clients.
• Almac Group: Northern Ireland-based Almac delivers formulation development, GMP manufacturing, and clinical trial services alongside proprietary drug delivery technologies, making it one of the closest scaled comparables to BDD Pharma's integrated CRO/CDMO plus tech platform model.
• MedPharm: MedPharm specialises in topical, transdermal, and other complex formulation development with in vitro/in vivo performance testing, mirroring BDD's specialist drug delivery formulation focus for challenging dosage forms.
• Onyx Scientific: Onyx Scientific is a UK-based CDMO offering API manufacturing, formulation development, and GMP clinical supplies, comparable to BDD's small-molecule drug product and CTM manufacturing capabilities.

Broad incumbents

• Charles River Laboratories: Charles River is a major CRO with a research models and CDMO footprint that bids for early-phase drug development contracts overlapping BDD's Phase I clinical and formulation development offerings.
• ICON plc: ICON is one of the largest global CROs with extensive early-phase clinical operations; it competes for Phase I trial contracts alongside BDD, particularly for biotech sponsors seeking integrated service offerings.
• Lonza: Lonza is a global CDMO leader with extensive small-molecule drug product and clinical services capabilities; while much larger, it competes for early-phase formulation and clinical trial supply contracts similar to BDD's core services.
• Catalent: Catalent is one of the largest global CDMOs offering oral dose formulation, softgel, and clinical supply services; it acquired Juniper Pharma Services in 2018, validating the broader CDMO + clinical services adjacency in which BDD operates at smaller scale.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=-WzQj1OJ8pQ
• Facebookfacebook.com/clinicaltrialsscotland
• Xx.com/BDD_Pharma
• LinkedInlinkedin.com/company/2177957

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Images Drug Delivery